CO5170404A1 - Terapia para melanomas - Google Patents
Terapia para melanomasInfo
- Publication number
- CO5170404A1 CO5170404A1 CO00025236A CO00025236A CO5170404A1 CO 5170404 A1 CO5170404 A1 CO 5170404A1 CO 00025236 A CO00025236 A CO 00025236A CO 00025236 A CO00025236 A CO 00025236A CO 5170404 A1 CO5170404 A1 CO 5170404A1
- Authority
- CO
- Colombia
- Prior art keywords
- patient
- pegylated interferon
- interferon alfa
- time
- melanomas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
El uso de interferon alfa pegilado para la manufactura de un medicamento para el tratamiento de un paciente que tiene melanoma que ha sido removido quirúrgicamente, en donde dicho medicamento es administrado a dicho paciente en una dosis terapéuticamente eficaz de interferon alfa pegilado por un periodo de tiempo suficiente para incrementar el tiempo de supervivencia libre de progresión.El uso de interferon alfa pegilado para la manufactura de un medicamento para el tratamiento de un paciente que tiene melanoma cutáneo que ha sido removido quirúrgicamente, en donde dicho medicamento es administrado a dicho paciente en una dosis terapéuticamente eficaz de interferon alfa pegilado una vez por semana por un periodo de tiempo suficiente para incrementar el tiempo de supervivencia libre de progresión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28836699A | 1999-04-08 | 1999-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5170404A1 true CO5170404A1 (es) | 2002-06-27 |
Family
ID=23106795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00025236A CO5170404A1 (es) | 1999-04-08 | 2000-04-06 | Terapia para melanomas |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP1535622B1 (es) |
JP (1) | JP2000319195A (es) |
CN (1) | CN1390132A (es) |
AR (1) | AR023398A1 (es) |
AT (3) | ATE496631T1 (es) |
AU (1) | AU771569B2 (es) |
BR (1) | BR0009646A (es) |
CA (1) | CA2303992A1 (es) |
CO (1) | CO5170404A1 (es) |
CY (1) | CY1108922T1 (es) |
DE (3) | DE60041290D1 (es) |
DK (2) | DK1043026T3 (es) |
ES (2) | ES2239954T3 (es) |
HK (2) | HK1032349A1 (es) |
HU (1) | HU230057B1 (es) |
MY (1) | MY126763A (es) |
NO (1) | NO328111B1 (es) |
PE (1) | PE20010027A1 (es) |
PT (2) | PT1043026E (es) |
TW (1) | TWI292320B (es) |
WO (1) | WO2000061175A2 (es) |
ZA (1) | ZA200108173B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4492537A (en) | 1982-12-10 | 1985-01-08 | Awerkamp John B | Fluid-operated oil or water well pump |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
DK0730470T3 (da) | 1993-11-10 | 2002-06-03 | Enzon Inc | Forbedrede interferonpolymerkonjugater |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
-
2000
- 2000-04-06 PE PE2000000310A patent/PE20010027A1/es not_active Application Discontinuation
- 2000-04-06 DE DE60041290T patent/DE60041290D1/de not_active Expired - Lifetime
- 2000-04-06 AT AT08020311T patent/ATE496631T1/de not_active IP Right Cessation
- 2000-04-06 EP EP05002951A patent/EP1535622B1/en not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009129 patent/WO2000061175A2/en active Application Filing
- 2000-04-06 HU HU0200775A patent/HU230057B1/hu not_active IP Right Cessation
- 2000-04-06 ES ES00107101T patent/ES2239954T3/es not_active Expired - Lifetime
- 2000-04-06 DE DE60045591T patent/DE60045591D1/de not_active Expired - Lifetime
- 2000-04-06 PT PT00107101T patent/PT1043026E/pt unknown
- 2000-04-06 DE DE60020444T patent/DE60020444T2/de not_active Expired - Lifetime
- 2000-04-06 ES ES05002951T patent/ES2319776T3/es not_active Expired - Lifetime
- 2000-04-06 PT PT05002951T patent/PT1535622E/pt unknown
- 2000-04-06 DK DK00107101T patent/DK1043026T3/da active
- 2000-04-06 AT AT00107101T patent/ATE296639T1/de active
- 2000-04-06 DK DK05002951T patent/DK1535622T3/da active
- 2000-04-06 CN CN00808452A patent/CN1390132A/zh active Pending
- 2000-04-06 AU AU42046/00A patent/AU771569B2/en not_active Ceased
- 2000-04-06 AR ARP000101574A patent/AR023398A1/es unknown
- 2000-04-06 TW TW089106309A patent/TWI292320B/zh not_active IP Right Cessation
- 2000-04-06 JP JP2000105524A patent/JP2000319195A/ja not_active Withdrawn
- 2000-04-06 EP EP00107101A patent/EP1043026B1/en not_active Expired - Lifetime
- 2000-04-06 AT AT05002951T patent/ATE419001T1/de active
- 2000-04-06 CA CA002303992A patent/CA2303992A1/en not_active Abandoned
- 2000-04-06 CO CO00025236A patent/CO5170404A1/es not_active Application Discontinuation
- 2000-04-06 BR BR0009646-6A patent/BR0009646A/pt not_active Application Discontinuation
- 2000-04-06 EP EP08020311A patent/EP2025344B1/en not_active Expired - Lifetime
- 2000-04-07 MY MYPI20001454A patent/MY126763A/en unknown
-
2001
- 2001-03-26 HK HK01102202A patent/HK1032349A1/xx not_active IP Right Cessation
- 2001-10-04 ZA ZA200108173A patent/ZA200108173B/en unknown
- 2001-10-05 NO NO20014852A patent/NO328111B1/no not_active IP Right Cessation
-
2005
- 2005-11-02 HK HK05109748.1A patent/HK1075416A1/xx not_active IP Right Cessation
-
2009
- 2009-03-24 CY CY20091100351T patent/CY1108922T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1173178E (pt) | Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil | |
PT95169A (pt) | Forma de dosagem para administracao de glipizida hipoglicemica por via oral | |
AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
MX9203443A (es) | Una forma de dosis para el suministro retardado de un farmaco. | |
NO20032027D0 (no) | Effektive antitumorbehandlinger | |
HK1077215A1 (en) | A pharmaceutical composition for treatment of acute myocardial infarction | |
CO5540323A2 (es) | Administracion oral de hormona paratiroides y calcitonina | |
AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
FI20011464A0 (fi) | Yhdistelmäterapia sydämen vajaatoiminnan hoitoon | |
CO5170404A1 (es) | Terapia para melanomas | |
AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
ATE247462T1 (de) | Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist | |
AR047154A1 (es) | Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol | |
AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
DK1265629T3 (da) | Anvendelse af væksthormon i lav dosis | |
MX9306998A (es) | Una composicion terapeutica de tandospirona y forma de dosis paraadministrarla. | |
PE20010226A1 (es) | Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |